Poorly water-soluble APIs present a variety of challenges in all phases of pharmaceutical R&D. In discovery, low solubility and bioavailability may mean that efficacy after oral administration cannot be properly assessed. API availability is typically limited in the discovery stage, which precludes extensive formulation development.

Using our miniaturized formulation design platforms, we provide our clients access to the entire range of solubility-enhancing technologies in their discovery programs.